Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.

Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.

A Food and Drug Administration (FDA) safety communication in August 2011 warned that citalopram was associated with a dose dependent risk of QT prolongation and recommended dose restriction in patients over the age of 60 but did not provide data for this age group.CitAD was a randomized, double-mask...

Full description

Bibliographic Details
Main Authors: Lea T Drye, David Spragg, D P Devanand, Constantine Frangakis, Christopher Marano, Curtis L Meinert, Jacobo E Mintzer, Cynthia A Munro, Gregory Pelton, Bruce G Pollock, Anton P Porsteinsson, Peter V Rabins, Paul B Rosenberg, Lon S Schneider, David M Shade, Daniel Weintraub, Jerome Yesavage, Constantine G Lyketsos, CitAD Research Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4051660?pdf=render

Internet

http://europepmc.org/articles/PMC4051660?pdf=render

Similar Items